Wall Street Analysts Have Consensus Hold Recommendation For Baxter International Inc. (BAX)

Baxter International Inc. (NYSE:BAX) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On December 2, Morgan Stanley analyst Patrick Wood cut his price target on the stock to $15 from $19 while keeping an Underweight rating.

Looking ahead to 2026, the analyst told investors in a research note that medical technology companies were well-placed, given the favorable trend in hospital spending, key product launches, and low stock valuations.

The adjustment follows Argus Research’s downgrading of Baxter International Inc. (NYSE:BAX) on October 31, citing a significant dividend reduction, effective from January 2026, with the company expecting the decision to drive a $300 million or higher boost in annual cash flow. These funds will be used to support de-leveraging efforts to strengthen the balance sheet.

Argus’ analysts also expressed concerns around the weak outlook for the company’s IV fluid solutions business.

As of the close of business on December 5, Wall Street analysts have a consensus Hold rating for the stock, with a one-year average share price target of $23.80, representing an upside potential of 28%.

Baxter International Inc. (NYSE:BAX) is a global medical technology company offering a wide range of healthcare products. The stock has had a challenging year, slumping 36% year to date.

While we acknowledge the potential of BAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Drone Stocks to Buy Right Now and 8 Best Small-Cap Defense Stocks to Buy Right Now 

Disclosure: None.